Blueprint Medicines Corporation Stock News

Deciphera price target raised to $55 from $50 at SVB Leerink SVB Leerink DCPH BPMC

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aptinyx (APTX), Iovance Biotherapeutics (IOVA) and

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aptinyx ( APTX – Research Report ), Iovance Biotherapeutics ( IOVA – Research Report ) and Blueprin

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zynex (ZYXI), Masimo (MASI) and Blueprint Medicines (BPMC). Zynex (ZYXI)

Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Hormel Foods, Tyson Foods and Zebra Technologies on Wednesday. HIGHLIGHTS

Fly Intel: Wall Street's top stories at midday BA MMM CAT UPS MRK PFE PEP MNST SNDX FFIV CGNX BPMC HLIT LRN

A closely watched drug candidate didn't meet the primary endpoint of a late-stage trial, which creates a wide-open opportunity for a competitor.

Blueprint Medicines Corp (NASDAQ: BPMC) shares were taking a beating Tuesday after the company announced a negative late-stage readout for its lead asset avapritinib in...

The growth of NSCLC Market is expected to increase due to increasing incident cases of NSCLC, continuous uptake of approved therapies mainly immune checkpoint inhibitors, increasing use of biomarker t

JonesTrading sees Deciphera as takeover target after Blueprint study miss JonesTrading DCPH BPMC

Right now, Blueprint Medicines Inc. (NASDAQ: BPMC) share price is at $59.15, after a 16.6% decrease. Over the past month, the stock spiked by 1.15%, but over the past year, it actually decreased by 20

Fly Intel: Pre-market Movers UPS MRK DGX QTNT FFIV HOG BPMC SDC PEP MMM CAT

Blueprint Medicines (NASDAQ:BPMC) slumps 15% premarket in reaction to its announcement that a Phase 3 clinical trial, VOYAGER, evaluating lead candidate avapritinib, branded as Ayvakit, in patients

Blueprint Medicines Corp:

Blueprint Medicines announces results from the Phase 3 VOYAGER clinical trial BPMC